Literature DB >> 22819139

Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy.

Murielle Mary-Krause1, Jean-Paul Viard2, Béatrice Ename-Mkoumazok3, Michelle Bentata4, Marc-Antoine Valantin5, Pascale Missy3, Iuliana Darasteanu3, Christian Roux6, Sami Kolta6, Dominique Costagliola7, Sylvie Rozenberg8.   

Abstract

We analyzed data collected during screening for eligibility in the ANRS-120 FOSIVIR clinical trial to estimate the prevalence of osteoporosis in patients infected with human immunodeficiency virus 1 (HIV-1), to study its risk factors, and to develop a screening strategy. McNemar test was used to compare the estimated prevalence of osteoporosis, using 3 different definitions. We then derived a screening strategy for HIV-infected men. We analyzed data for 700 men and 192 women. The prevalence of osteoporosis differed markedly according to the definition used. Based on the "T-score ≤ -2.5" definition, 14.9% of men and 1.0% of women had osteoporosis. Factors associated with low bone mineral density comprised not only classical risk factors for osteoporosis such as low body mass index (BMI) or older age but also factors associated with HIV infection such as lower CD4 T-cell nadir in men and AIDS in women, and with antiretroviral treatment such as recent tenofovir therapy. In addition to postmenopausal women, we recommend osteoporosis screening for HIV-infected men older than 60 yr, men younger than 60 yr with BMI < 20 kg/m(2), and men younger than 60 yr with both BMI 20-23 kg/m(2) and a CD4 T-cell nadir ≤ 200/mm(3).
Copyright © 2012 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22819139     DOI: 10.1016/j.jocd.2012.04.001

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  9 in total

Review 1.  Antiretroviral therapy: when to start.

Authors:  Christopher J Sellers; David A Wohl
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

2.  Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Authors:  David V Glidden; Kathleen Mulligan; Vanessa McMahan; Peter L Anderson; Juan Guanira; Suwat Chariyalertsak; Susan P Buchbinder; Linda Gail Bekker; Mauro Schechter; Beatriz Grinsztejn; Robert M Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

3.  Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Kathleen Mulligan; David V Glidden; Peter L Anderson; Albert Liu; Vanessa McMahan; Pedro Gonzales; Maria Esther Ramirez-Cardich; Sirianong Namwongprom; Piotr Chodacki; Laura Maria Carvalo de Mendonca; Furong Wang; Javier R Lama; Suwat Chariyalertsak; Juan Vicente Guanira; Susan Buchbinder; Linda-Gail Bekker; Mauro Schechter; Valdilea G Veloso; Robert M Grant
Journal:  Clin Infect Dis       Date:  2015-04-23       Impact factor: 9.079

Review 4.  How to predict the risk of fracture in HIV?

Authors:  Michael T Yin; Julian Falutz
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

5.  Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.

Authors:  Matthew A Spinelli; David V Glidden; Peter L Anderson; Monica Gandhi; Vanessa M McMahan; Patricia Defechereux; Mauro Schechter; Valdiléa G Veloso; Suwat Chariyalertsak; Juan V Guanira; Linda-Gail Bekker; Susan P Buchbinder; Robert M Grant
Journal:  AIDS Res Hum Retroviruses       Date:  2019-06-19       Impact factor: 2.205

6.  Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Authors:  D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

Review 7.  Osteoporosis in Human Immunodeficiency Virus Patients - An Emerging Clinical Concern.

Authors:  Filippo Maffezzoni; Teresa Porcelli; Ioannis Karamouzis; Eugenia Quiros-Roldan; Francesco Castelli; Gherardo Mazziotti; Andrea Giustina
Journal:  Eur Endocrinol       Date:  2014-02-28

8.  The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.

Authors:  Jessica L Feig; Aranzazu Mediero; Carmen Corciulo; Hailing Liu; Jin Zhang; Miguel Perez-Aso; Laura Picard; Tuere Wilder; Bruce Cronstein
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

9.  Osteopenia and osteoporosis among treatment-experienced people living with HIV.

Authors:  Bárbara Marques de Castro Lara; Cristiane Menezes de Pádua; Cássia Cristina Pinto Mendicino; Gustavo Machado Rocha
Journal:  Braz J Infect Dis       Date:  2020-06-15       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.